Effect of long-term treatment with low-dose mifepristone on the endometrium

Human Reproduction

Volumn 18, Issue 1, 2003, Pages 61-68

  Baird, D T ^a   Brown, A ^a   Critchley, H O D ^a   Williams, A R ^b   Lin, S ^c   Cheng, L ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Shanghai Institute of Family Planning Technical Instruction   (China)

Author keywords

Antigestogen; Antiproliferation; Contraception; Mifepristone

Indexed keywords

ESTROGEN; ESTRONE GLUCURONIDE; KI 67 ANTIGEN; MIFEPRISTONE; MONOCLONAL ANTIBODY KI 67; PLACEBO; PROGESTERONE;

ADULT; AMENORRHEA; ARTICLE; CELL PROLIFERATION; CHINA; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ESTROGEN SYNTHESIS; FEMALE; FOLLICULAR PHASE; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; MITOSIS INDEX; NORMAL HUMAN; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVULATION INHIBITION; PILL; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; STOMACH DISEASE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED KINGDOM;

EID: 0037251659     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deg022     Document Type: Article

References (30)

1. Aldercreutz, H., Gorbach, S.L., Goldin, B.R., Woods, M.N., Dwyer, J.J. and Hamalainen, E. (1994) Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl. Cancer Inst., 86, 1076-1082.
2. Anderson, R.A. and Wu, F.C.W. (1996) Comparison between testosterone enanthate-induced azoospermia and oligospermia in a male contraceptive study III: Higher 5α-reductase activity in oligospermic responders during testosterone enanthate administration. Clin. Endocrinol., 81, 902-908.
3. Baird, D.T. (2001) Antigestogens: The holy grail of contraception. Reprod. Fertil. Dev., 13, 1-6.
4. Baird, D.T. and Glasier, A.F. (1990) Science, medicine and the future: Contraception. Br. Med. J., 319, 969-972.
5. Brenner, R.M., Slayden, O.D. and Critchley, H.O.D. (2002) Antiproliferative effects of progesterone antagonists in the primate endometrium; A potential role for the androgen receptor. Reproduction, 124, 167-172.
6. Brown, A., Cheng, L., Lin, S. and Baird, D.T. (2002) Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double blind randomised control trial of 2 and 5mg per day for 120 days. J. Clin. Endocrinol. Metab., 87, 63-70.
7. Cameron, S.T., Thong, K.J. and Baird, D.T. (1995) Effect of daily low dose mifepristone on the ovarian cycle and on the dynamics of follicle growth. Clin. Endocrinol., 43, 407-414.
8. Cameron, S.T., Critchley, H.O.D., Thong, K.J., Buckley, C.H., Williams, A.R. and Baird, D.T. (1996) Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod., 11, 2518-2526.
9. Chwalisz, K., Brenner, R.M., Fuhrmann, UU., Hess-Stump, H. and Elger, W. (2000) Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids, 65, 741-751.
10. Croxatto, H.B., Salvatierra, A.M., Croxatto, H.D. and Fuentealba, B. (1993) Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod., 8, 201-207.
11. Croxatto, H.B., Kovacs, L., Massai, R., Resch, B.A., Fuentealba, B., Salvatierra, A.M., Croxatto, H.D., Zalanyi, S., Viski, S. and Krenacs, L. (1998) Effects of long term low-dose mifepristone on reproductive function in women. Hum. Reprod., 13, 793-798.
12. Den Tonkelaar, I. and Oddens, B.J. (1999) Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use and hormone replacement therapy use. Contraception, 59, 357-362.
13. Fraser, I.S. (2000) Progestogen-only contraception. In Glasier, A.F. and Gebbie, A (eds), Handbook of Family Planning and Reproductive Healthcare. Churchill Livingstone, Edindburgh, pp. 77-103.
14. Gravanis, A., Schaison, G., George, M., DeBrux, J., Satyaswaroop, G., Baulieu, E-E. and Rubel, P. (1985) Endometrial and pituitary responses to the steroid antiprogestogen RU486 in post menopausal women. J. Clin. Endocrinol. Metab., 60, 156-163.
15. Heikinheimo, O.J.G., Hsiu, J.G., Gordon, K., Kim, S., Williams, R.F., Gibbons, W.E. and Hodgen, G.D. (1996) Endometrial effects of RU486 in primates - Antiproliferative action despite signs of oestrogen action and increased cyclin-B expression. J. Steroid Biochem. Mol. Biol., 59, 179-190
16. Ishwad, P.C., KatKam, R.R., Hinduta, I.N., Chwalisz, K., Elger, W. and Puri, C.D. (1993) Treatment with a progesterone antagonist ZK 98,299 delays endometrial development without blanking ovulation in Bonnet Monkeys. Contraception, 48, 57-70.
17. Kettel, L.M., Murphy, A.A., Mortola, J.F., Liu, J.H., Ulmann, A. and Yen, S.S.C. (1991) Endocrine responses to long-term administratin of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil. Steril., 56, 402-407.
18. Kettel, L.M., Murphy, A.A., Morales, A.J., Baulieu, E-E. and Yen, S.S.C. (1996) Treatment of endometriosis with antiprogesterone mifepristone (RU486). Fertil. Steril., 65, 23-28.
19. Key, T.J.A., Chen, J., Wang, D.Y., Pike, M.C. and Boreham, J. (1990) Sex hormones in women in rural China and in Britain. Br. J. Cancer, 62, 631-636.
20. Kurman, R. and Norris, H.J. (1994) Endometrial hyperplasia and related cellular changes. Blaustein's Pathology of the Female Genital Tract, 4th edn. Springer-Verlag, New York, p. 412.
21. Ledger, W.L., Sweeting, V.M., Hillier, H. and Baird, D.T. (1992) Inhibition of ovulation by low dose mifepristone (RU486). Hum. Reprod., 7, 945-950.
22. Murphy, A.A., Kettel, L.M., Morales, A.J., Roberts, V., Parmley, T. and Yen, S.S.C. (1995) Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril., 63, 761-766.
23. Neulen, J., Williams, R.F., Breckwoldt, M., Chwalisz, K., Baulieu, E-E. and Hodgen, G.D. (1995) Non-competitive anti-oestrogen actions of progesterone antagonists in primate endometrium: Enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum. Reprod., 11, 1533-1537.
24. Newfield, R.S., Spitz, I.M., Isacson, C. and New, M.I. (2001) Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinil. (Oxf.), 54, 399-404.
25. Sitruk-Ware, R. (2000) Approval of mifepristone (RU486) in Europe. Zentrabl. Gynakol., 122, 241-247.
26. Skegg, D.C.G. (2000) Third generation oral contraceptives. Br. Med. J., 7255, 190-191.
27. Slayden, O.D., Zelinski-Wooten, M.B., Chwalisz, K., Stouffer, R.L. and Brenner, R.M. (1998) Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK137316: Morphometric analysis of the uterus and oviduct. Hum. Reprod., 13, 269-277.
28. Slayden, O.D., Nayak, N.R., Burton, N.R., Chwalisz, K., Cameron, S.T., Critchley, H.O.D., Baird, D.T. and Brenner, R.M. (2001) Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J. Clin. Endocrinol. Metab., 86, 2668-2679.
29. Ulmann, A. (2000) The development of mifepristone: A pharmaceutical drama in three acts. J. Am. Med Women's Assoc., 55 (Suppl. 3), 117-120.
30. Van Vem, J.F.H.M., Hsiu, J.G., Chillik, C.F., Danforth, D.R., Ulmann, A., Baulieu, E-E. and Hodgen, G.D. (1989) Contraceptive potential of RU486 by ovulation inhibition: Pituitary versus ovarian action with blockade of estrogen induced endometrial proliferation. Contraception, 40, 171-183.